05:27 AM EDT, 07/10/2025 (MT Newswires) -- Nurix Therapeutics ( NRIX ) reported a fiscal Q2 net loss late Wednesday of $0.52 per diluted share, compared with a $0.71 loss a year earlier.

Analysts polled by FactSet expected a $0.71 loss.

Revenue for the quarter ended May 31 was $44.1 million, up from $12.1 million a year earlier.

Analysts surveyed by FactSet expected $17.5 million.

The increase was mainly due to $30 million of license revenue from the achievement of two Sanofi ( SNY ) license extensions and a $5 million clinical milestone achieved under Nurix's collaboration with Gilead Sciences ( GILD ) during the quarter, the company said.

Nurix shares were up nearly 50% in recent premarket activity Thursday.